Core Insights - Public fundraising enthusiasm has rebounded this year, with 74 A-share companies involved in public placements, totaling 30.292 billion yuan, a year-on-year increase of 28.5% [1][2] Group 1: Industry Performance - The electronic industry is the most favored by public institutions, with 13 electronic stocks attracting a total of 8.986 billion yuan in public placements [2] - The pharmaceutical and biotechnology sector follows, with 6 stocks, including Baili Tianheng and Dize Pharmaceutical, raising a total of 4.518 billion yuan [2] Group 2: Investment Gains - Among the 74 stocks involved in public placements, 71 are currently in a profit state, with 39 stocks having a profit margin within 50%, 12 stocks between 50%-99.99%, and 7 stocks exceeding 100% [1] - A total of 36 public institutions have achieved profits from their investments, representing 97.30% of the participants, with varying profit margins across different institutions [2]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-55 迪哲（江苏）医药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 10 月 27 日（星期一）至 10 月 31 日（星期 五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 IR@dizalpharma.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 迪哲（江苏）医药股份有限公司（以下简称"公司"）将于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 03 日（星期一）下午 15:00-16:00 举行 2025 年第 三季度业绩说明会，就投资者关心的问题进行交流。 1 会议召开时间：2025 年 11 月 03 日（星期一）15:00-16:00 会议召开地点：上海证 ...

中国创新药迎来密集出海潮。 中国学者在国际医疗学界的影响力与中国创新药在全球的竞争力是同步在提升的。 2019年，中国终于有自主研发的抗癌药成功获批在美国上市，实现零的突破。自此之后，中国创新药走 向海外市场上市，按下了加速键。 截至目前，在海外上市的国产创新药，数量超过20款。 在近日举办的2025年欧洲肿瘤内科学会（ESMO）年会上，中国肿瘤领域的研究再度成为焦点。 由中国学者主导的入选"突破性摘要"研究高达23项，创下历史新高，同时还有3项重磅成果进入最高学 术等级的"主席论坛"进行口头报告。 十年前，中国创新药在全球市场还默默无闻，如今已在崭露头角，融入全球医药版图中，也成为全球创 新贡献力量之一。"十四五"期间，伴随着越来越多的中国创新治疗方案闪亮登上国际舞台，中国创新药 迎来了密集出海潮。 在这个过程中，中国创新药从模仿到跟随，正向源头创新转型。 密集出海潮 今年9月8日，国际肺癌研究协会迎来换届，比利时安特卫普大学医院Paul Van Schil教授正式卸任，同济 大学附属东方医院周彩存教授接任新一届主席，任期自2025年至2027年，这是该协会成立以来首位来自 中国大陆的主席。 最初，医药行业 ...

从行业分布看，电子与医药生物等行业受到公募机构的青睐。在电子行业的定增个股中，寒武纪、盛美 上海、芯原股份等10余只个股获得公募机构认购，总额达89.86亿元；医药生物行业则有百利天恒、迪 哲医药等6只个股获青睐，公募机构认购总额为45.18亿元。此外，电力设备、基础化工和有色金属行业 的公募机构认购总额也均超10亿元。 业内人士认为，公募机构积极参与上市公司定增，不仅反映其对市场机会的敏锐捕捉，也折射出定增市 场生态的优化。一方面，政策利好与产业升级推动优质项目供给增加；另一方面，公募机构的专业研究 能力与资金规模优势，使其在定增市场中占据主动。随着A股市场国际化与机构专业化程度提升，定增 作为重要的再融资工具，其长期价值有望进一步凸显。 今年以来，公募机构参与上市公司定向增发(定增)的热情持续攀升。公募排排网数据显示，截至10月22 日(按定增上市日统计)，年内共有37家公募机构参与74家A股上市公司的定增项目，覆盖电子、医药等 18个行业，认购总额达302.92亿元，较去年同期的235.73亿元增长28.50%。按10月22日收盘价计算，目 前公募机构参与定增的浮动盈利金额已达108.45亿元，展现出可 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.32% on October 22, with Dize Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Xiangdi Pharmaceutical (301211) with a closing price of 14.99, up 14.25% [1] - Duorui Pharmaceutical (301075) at 58.62, up 10.21% [1] - Guangji Pharmaceutical (000952) at 7.77, up 10.06% [1] - Hasi Lian (002900) at 14.61, up 10.02% [1] - Yatai Pharmaceutical (002370) at 7.70, up 10.00% [1] - Dize Pharmaceutical (688192) was the biggest loser, closing at 60.11, down 6.20% [2] - Other significant decliners included: - Kangzhiyue Pharmaceutical (300086) down 5.90% [2] - Puluo Pharmaceutical (000739) down 5.41% [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 185 million yuan from institutional investors, while retail investors experienced a net inflow of 41.4 million yuan [2] - However, speculative funds recorded a net outflow of 227 million yuan [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Yatai Pharmaceutical (002370) with a net inflow of 2.38 billion yuan from institutional investors, but a net outflow of 95.28 million yuan from speculative funds [3] - Anglikang (002940) had a net inflow of 182 million yuan from institutional investors, with a net outflow of 97.14 million yuan from speculative funds [3] - Hasi Lian (002900) recorded a net inflow of 117 million yuan from institutional investors, but a significant net outflow of 59.36 million yuan from speculative funds [3]

迪哲医药-U10月21日大宗交易平台出现一笔成交，成交量6.93万股，成交金额444.31万元，大宗交易成 交价为64.08元。该笔交易的买方营业部为中信证券股份有限公司总部(非营业场所)，卖方营业部为机构 专用。 10月21日迪哲医药-U大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营业部 | 卖方营 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | | 业部 | | | | | | 中信证券股份有限公司总部 | 机构专 | | 6.93 | 444.31 | 64.08 | 0.00 | (非营业场所) | 用 | （文章来源：证券时报网） 进一步统计，近3个月内该股累计发生2笔大宗交易，合计成交金额为879.63万元。 证券时报·数据宝统计显示，迪哲医药-U今日收盘价为64.08元，上涨2.07%，日换手率为1.13%，成交额 为3.24亿元，全天主力资金净流入1391.87万元，近5日该股累计上涨0.22%，近5日资金合计净流入 2512.04万元。 两融数据显示，该股最新融资 ...

| | | | | | | on the property and any and | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司是参院留意思 | 机构专用 | 2025-10-21 | 迪曾医药 | 688192 | 64.08 | 444.31 | 6.93 | 百 | 1999 | 10月21日，迪哲医药大宗交易成交6.93万股，成交额444.31万元，占当日总成交额的1.35%，成交价 64.08元，较市场收盘价64.08元持平。 ...

| 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营业部 | 卖方营 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | | 业部 | | 6.93 | 435.32 | 62.78 | 0.00 | 中信证券股份有限公司总部 | 机构专 | | | | | | (非营业场所) | 用 | （文章来源：证券时报网） 证券时报·数据宝统计显示，迪哲医药-U今日收盘价为62.78元，下跌4.08%，日换手率为2.03%，成交额 为5.79亿元，全天主力资金净流入2525.36万元，近5日该股累计下跌5.88%，近5日资金合计净流出 1397.72万元。 两融数据显示，该股最新融资余额为1.43亿元，近5日增加100.62万元，增幅为0.71%。（数据宝） 10月20日迪哲医药-U大宗交易一览 迪哲医药-U10月20日大宗交易平台出现一笔成交，成交量6.93万股，成交金额435.32万元，大宗交易成 交价为62.78元。该笔交易的买方营业部为中信证券股份有限公司总部(非营业场所)，卖方营业部为机构 专用。 ...

Core Viewpoint - On October 20, a total of 9 stocks from the Sci-Tech Innovation Board (STAR Market) experienced block trading, with a cumulative transaction amount of 165 million yuan [1][2]. Group 1: Trading Overview - There were 23 block trades executed, totaling a volume of 2.4156 million shares and an aggregate transaction value of 165 million yuan [1]. - The stock with the highest transaction amount was Bawei Storage, with 3 block trades totaling 536,026 shares and a transaction value of 50.3626 million yuan [1]. - Other notable stocks in terms of transaction value included Honghua Digital Science and Dameng Data, with transaction amounts of 43.7311 million yuan and 18.8032 million yuan, respectively [1]. Group 2: Price Performance - The average discount rates for block trades relative to the closing prices were highest for Bolivian, Dameng Data, and Dekeli, with discount rates of 29.36%, 20.75%, and 12.24% respectively [1]. - Stocks with the highest premium rates included Dize Pharmaceutical and Lair Technology, both at 0.06% [1]. - The STAR 50 Index rose by 0.35%, with 447 stocks (76.02%) on the STAR Market increasing in value, while the average increase for stocks involved in block trading was 1.75% [1]. Group 3: Institutional Participation - Among the block trades, there were 5 transactions involving institutional buyers or sellers, covering 3 stocks [2]. - The leading stocks for institutional buying were Bawei Storage and Honghua Digital Science, with buying amounts of 46.98 million yuan and 9.8986 million yuan, respectively [2]. - The stocks with the highest net inflow of funds included Dekeli, Dize Pharmaceutical, and Bawei Storage, with net inflows of 82.1361 million yuan, 25.2536 million yuan, and 6.3566 million yuan, respectively [2].

Group 1 - A total of 56 stocks in the A-share market experienced block trading today, with a total transaction value of 1.168 billion yuan [1] - The top three stocks by transaction value were Hengli Petrochemical (220 million yuan), Wantong Development (99.9929 million yuan), and Chuangye Huikang (68.4 million yuan) [1] - Among the stocks, 7 were traded at par, 4 at a premium, and 45 at a discount; the highest premium rates were for Aidi Precision (4.02%), Hengli Petrochemical (0.86%), and Lier Technology (0.06%) [1] Group 2 - The stocks with the highest discount rates included Boliview (29.35%), Yuxin Electronics (21.36%), and Zhongji Xuchuang (21.09%) [1] - The ranking of institutional buy amounts showed Chuangye Huikang leading with 66.24 million yuan, followed by Jinlong Co. (51.3405 million yuan) and Baiwei Storage (46.98 million yuan) [1] - The top three stocks by institutional sell amounts were Longqi Technology (13.008 million yuan),招商公路 (6.156 million yuan), and Dize Pharmaceutical-U (4.3532 million yuan) [2]